Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

R-Pharm

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: Ixabepilone

Study type: Interventional

Funder types: Industry

Identifiers

NCT01018966

CA163-029

Details and patient eligibility

About

The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.

Enrollment: 25 estimated patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 20 years or older
• Histologically or cytologically confirmed diagnosis of adenocarcinoma Solid tumors

Exclusion criteria

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥2

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Ixabepilone

Experimental group

Treatment:

Drug: Ixabepilone